AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
While most of the children spontaneously recover menstruation or experienced normal puberty after chemotherapy, their ovarian reserve may be impaired by treatment inducing future infertility. Fertility preservation is currently proposed for selected prepubertal patients with a high risk of premature ovarian failure after treatment (mostly conditioning regimen for bone marrow transplantation). For patients with low or moderate risks, counselling is very difficult and no fertility preservation procedure is usually proposed for these patients as no marker of the ovarian reserve has been validated in this young population to assess the individual risk. The primary objective of the study is to prevent long-term treatment-related infertility by detecting the young patients who normally progressed to menarche but have a reduced ovarian reserve. These patients may benefit from particular follow-up and fertility preservation procedure.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 3 do 14 lat
- •Wysokie ryzyko: chemioterapia przed przeszczepem szpiku kostnego lub napromienianie miednicy
- •Średnie/niskie ryzyko: określone rodzaje nowotworów (białaczka, chłoniak, guz Wilmsa i inne) leczone chemioterapią
- •Grupa kontrolna: dzieci z przewlekłymi chorobami niezakaźnymi lub rakami nie wymagającymi chemioterapii
✗ Disqualifies
- •Napromienianie mózgu lub guz mózgu
- •Poprzednie choroby lub operacje jajników
- •Rodzinna historia przedwczesnej niewydolności jajników
- •Poważne przewlekłe choroby wpływające na wzrost lub dojrzewanie (zaburzenia genetyczne, niekontrolowana cukrzyca, mukowiscydoza)
- •Zaburzenia genetyczne powodujące niepełnosprawność intelektualną
Simplified criteria — AI translation
Trial details
- Minimum age
- 3 Years
- Maximum age
- 14 Years
- Last updated (source)
- August 12, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (8)
Centre Hospitalier Chrétien (CHC)- Clinique de l'espérance
Montegnée, Belgium
Universitair Ziekenhuis Antwerpen
Antwerp, Belgium
Hôpital Universitaire Reine Fabiola (HUDERF)
Brussels, Belgium
Universitair Ziekenhuis Brussels
Brussels, Belgium
Universitair Ziekenhuis Leuven
Leuven, Belgium
Centre Hospitalier Régional (CHR)-Citadelle
Liège, Belgium
Centre Oscar Lambret
Lille, France
CHRU Lille-Hôpital Jeanne de Flandre
Lille, France
Trial contact
Isabelle Demeestere, PhD
Julie Dechene
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/13/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.